Phase IB/II Open‐label Single‐Arm Study to Evaluate Safety and Efficacy of Tucatinib in Combination With Palbociclib and Letrozole in Subjects With Hormone Receptor‐Positive and HER2‐positive Metastatic Breast Cancer. Here, NR4A1 is linked to breast cancer.